222 related articles for article (PubMed ID: 19132803)
1. Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain.
Valero A; de la Torre F; Castillo JA; Rivas P; del Cuvillo A; Antépara I; Borja J; Donado E; Molà O; Izquierdo I
Drug Saf; 2009; 32(1):33-42. PubMed ID: 19132803
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
[TBL] [Abstract][Full Text] [Related]
3. Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis.
Izquierdo I; Merlos M; García-Rafanell J
Drugs Today (Barc); 2003 Jun; 39(6):451-68. PubMed ID: 12944997
[TBL] [Abstract][Full Text] [Related]
4. Rupatadine: global safety evaluation in allergic rhinitis and urticaria.
González-Núñez V; Bachert C; Mullol J
Expert Opin Drug Saf; 2016 Oct; 15(10):1439-48. PubMed ID: 27500993
[TBL] [Abstract][Full Text] [Related]
5. Reduction of nasal volume after allergen-induced rhinitis in patients treated with rupatadine: a randomized, cross-over, double-blind, placebo-controlled study.
Valero A; Serrano C; Bartrá J; Izquierdo I; Muñoz-Cano R; Mullol J; Picado C
J Investig Allergol Clin Immunol; 2009; 19(6):488-93. PubMed ID: 20128424
[TBL] [Abstract][Full Text] [Related]
6. Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study.
Guadaño EM; Serra-Batlles J; Meseguer J; Castillo JA; De Molina M; Valero A; Picado C;
Allergy; 2004 Jul; 59(7):766-71. PubMed ID: 15180765
[TBL] [Abstract][Full Text] [Related]
7. Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study.
Potter P; Maspero JF; Vermeulen J; Barkai L; Németh I; Baillieau RA; Garde JM; Giralt J; Doménech A; Izquierdo I; Nieto A
Pediatr Allergy Immunol; 2013 Mar; 24(2):144-50. PubMed ID: 23384091
[TBL] [Abstract][Full Text] [Related]
8. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders.
Picado C
Expert Opin Pharmacother; 2006 Oct; 7(14):1989-2001. PubMed ID: 17020424
[TBL] [Abstract][Full Text] [Related]
9. Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study.
Martínez-Cócera C; De Molina M; Martí-Guadaño E; Pola J; Conde J; Borja J; Pérez I; Arnaiz E; Izquierdo I;
J Investig Allergol Clin Immunol; 2005; 15(1):22-9. PubMed ID: 15864879
[TBL] [Abstract][Full Text] [Related]
10. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis.
Fantin S; Maspero J; Bisbal C; Agache I; Donado E; Borja J; Mola O; Izquierdo I;
Allergy; 2008 Jul; 63(7):924-31. PubMed ID: 18588560
[TBL] [Abstract][Full Text] [Related]
11. Rupatadine in allergic rhinitis and chronic urticaria.
Mullol J; Bousquet J; Bachert C; Canonica WG; Gimenez-Arnau A; Kowalski ML; Martí-Guadaño E; Maurer M; Picado C; Scadding G; Van Cauwenberge P
Allergy; 2008 Apr; 63 Suppl 87():5-28. PubMed ID: 18339040
[TBL] [Abstract][Full Text] [Related]
12. Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber.
Stuebner P; Horak F; Zieglmayer R; Arnáiz E; Leuratti C; Pérez I; Izquierdo I
Ann Allergy Asthma Immunol; 2006 Jan; 96(1):37-44. PubMed ID: 16440531
[TBL] [Abstract][Full Text] [Related]
13. Rupatadine for the treatment of allergic rhinitis and urticaria.
Metz M; Maurer M
Expert Rev Clin Immunol; 2011 Jan; 7(1):15-20. PubMed ID: 21162645
[TBL] [Abstract][Full Text] [Related]
14. Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.
Solans A; Carbó ML; Peña J; Nadal T; Izquierdo I; Merlos M
Clin Ther; 2007 May; 29(5):900-908. PubMed ID: 17697908
[TBL] [Abstract][Full Text] [Related]
15. Rupatadine: a review of its use in the management of allergic disorders.
Keam SJ; Plosker GL
Drugs; 2007; 67(3):457-74. PubMed ID: 17335300
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.
Saint-Martin F; Dumur JP; Pérez I; Izquierdo I;
J Investig Allergol Clin Immunol; 2004; 14(1):34-40. PubMed ID: 15160440
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: A double-blind, randomized, multicenter, placebo-controlled clinical trial.
Okubo K; Suzuki T; Tanaka A; Aoki H
Allergol Int; 2019 Apr; 68(2):207-215. PubMed ID: 30391169
[TBL] [Abstract][Full Text] [Related]
18. Futura study: evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis.
Mion Ode G; Campos RA; Antila M; Rapoport PB; Rosario N; de Mello Junior JF; Guimarães RE; Mocellin M; Di Gesu G; Solé D; Wexler L; de Mello JF; Castro FM; Chavarria ML
Braz J Otorhinolaryngol; 2009; 75(5):673-9. PubMed ID: 19893935
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rupatadine for allergic rhino-conjunctivitis: a systematic review of randomized, double-blind, placebo-controlled studies with meta-analysis.
Compalati E; Canonica GW
Curr Med Res Opin; 2013 Nov; 29(11):1539-51. PubMed ID: 23826741
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis.
Katiyar S; Prakash S
Prim Care Respir J; 2009 Jun; 18(2):57-68. PubMed ID: 18695846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
